Advertisement

Ethical Analysis of Public Health Programmes: What Does It Entail?

  • Giridhara R. Babu
  • A. Yamuna
Chapter

Abstract

While several professions have ethical guidelines set by their own professional bodies, such guidance is often not available for implementation of public health programmes. Therefore, very often, ethical perspectives involving the public health programmes (PHPs) are neglected. As a result, several ethical issues arise during the implementation phase. This chapter examines three key principles, namely, respect to persons, beneficence, and justice, and explores its applicability to public health practice. It analyse this framework using three case studies: the Revised National Tuberculosis Control Program (RNTCP), introduction of Human Papilloma Virus (HPV) vaccines in India, and polio eradication (PE) programme. We used the published literature, reports of ongoing national programmes, and documents outlining ethical principles published by national and international organizations to analyse the components of the framework. Each case study informs the multifaceted dimensions of ethical issues and challenges associated with a specific programme. In the absence of clearly developed guidance, we illustrate how using our proposed framework can identify and resolve ethical issues in the existing public health programmes.

Keywords

Ethical analysis Public health programmes Respect for persons Beneficence Justice 

References

  1. Aneja, H., & Puliyel, J. (2009). Selling vaccines: Deciding on who can afford HPV. Indian Pediatrics, 46(7), 647.Google Scholar
  2. Association WM. (1964). Declaration of Helsinki. Ethical principles for medical research involving human subjects. Adopted by the 18th world medical association general assembly. Helsinki, Finland.Google Scholar
  3. Attaran, A. (2005). An immeasurable crisis? A criticism of the millennium development goals and why they cannot be measured. PLoS Medicine, 2(10), e318.CrossRefGoogle Scholar
  4. Babu, G. R. (2008). Comment on ‘From risk factors to explanation in public health’. Journal of Public Health.Google Scholar
  5. Babu, G. R. (2009). Response to ‘Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US’. International Journal of Epidemiology, 38(4), 1157–1158.  https://doi.org/10.1093/ije/dyn119.CrossRefGoogle Scholar
  6. Babu, G. R. (2012a). Evidence for health policy in India: Do we have enough data? Journal of Royal Society of Medicine, 105(9), 365–365.CrossRefGoogle Scholar
  7. Babu, G. R. (2012b). Evidence for health policy in India: Do we have enough data? Journal of the Royal Society of Medicine, 105(9), 365.CrossRefGoogle Scholar
  8. Babu, G. R., & Laxminarayan, R. (2012). The unsurprising story of MDR-TB resistance in India. Tuberculosis, 92(4), 301–306.  https://doi.org/10.1016/j.tube.2012.02.009.CrossRefGoogle Scholar
  9. Babu, G. R., & Murthy, G. (2011). “To use or not to use”-dilemma of developing countries in introducing new vaccines. Journal of Global Infectious Diseases, 3(4), 406.CrossRefGoogle Scholar
  10. Babu, G. R., Tn, S., Bhan, A., Lakshmi, J., & Kishore, M. (2014). An appraisal of the tuberculosis programme in India using an ethics framework. Indian Journal of Medical Ethics, 11(1), 11–15.Google Scholar
  11. Basu, M. (2006). The relevance of cervical cancer screening and the future of cervical cancer control in India in the light of the approval of the vaccine against cervical cancer. Indian Journal of Cancer, 43(3), 139.CrossRefGoogle Scholar
  12. Baum, N. M., Gollust, S. E., Goold, S. D., & Jacobson, P. D. (2007). Looking ahead: Addressing ethical challenges in public health practice. Los Angeles: Sage.Google Scholar
  13. Baum, N. M., Gollust, S. E., Goold, S. D., & Jacobson, P. D. (2009). Ethical issues in public health practice in Michigan. American Journal of Public Health, 99(2), 369–374.CrossRefGoogle Scholar
  14. Begum, V., Van Der Werf, M. J., Becx-Bleumink, M., & Borgdorff, M. W. (2007). Viewpoint: Do we have enough data to estimate the current burden of tuberculosis? The example of Bangladesh. Tropical Medicine & International Health, 12(3), 317–322.CrossRefGoogle Scholar
  15. Bernheim, R. G. (2003). Public health ethics: The voices of practitioners. The Journal of Law, Medicine & Ethics, 31(s4), 104–109.CrossRefGoogle Scholar
  16. Bernheim, R. G., Nieburg, P., & Bonnie, R. J. (2007). Ethics and the practice of public health. Law in Public Health Practice, 110–135.Google Scholar
  17. Bernheim et al. (2009) (January 2016). Adapted summary of a public health ethics framework Bernheim et al. (2009) Ethics and the practice of public health. Available at: http://www.ncchpp.ca/docs/2016_eth_frame_bernheim_En.pdf.
  18. Bhatla, N., & Moda, N. (2009). The clinical utility of HPV DNA testing in cervical cancer screening strategies. The Indian Journal of Medical Research, 130(3), 261.Google Scholar
  19. Bhaumik, S., & Biswas, T. (2012). India makes tuberculosis a notifiable disease. Canadian Medical Association Journal, 184(10), E519–E520.CrossRefGoogle Scholar
  20. Biomedical NCft PoHSo & BR. (1979). The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. Department of Health, Education, and Welfare.Google Scholar
  21. Caplan, A. L. (2009). Is disease eradication ethical? The Lancet, 373(9682), 2192–2193.CrossRefGoogle Scholar
  22. Chauhan, L., & Agarwal, S. (2005). Revised national tuberculosis control programme. Tuberculosis Control in India, p. 23.Google Scholar
  23. Childress, J. F., Faden, R. R., Gaare, R. D., Gostin, L. O., Kahn, J., Bonnie, R. J., et al. (2002). Public health ethics: Mapping the terrain. The Journal of Law, Medicine & Ethics, 30(2), 170–178.CrossRefGoogle Scholar
  24. Control Gt. (2011). W. report. pp. 25–26. Available at: http://whqlibdoc.who.int/publications/2011/9789241564380_eng.pdf. Accessed 26th October 2012.
  25. Detels, R., McEwen, J., Beaglehole, R., & Tanaka, H. (1999). Epidemiology: The foundation of public health. Oxford textbook of public health.Google Scholar
  26. Dewan, P. K., Lal, S., Lonnroth, K., Wares, F., Uplekar, M., Sahu, S., et al. (2006). Improving tuberculosis control through public-private collaboration in India: Literature review. BMJ, 332(7541), 574–578.CrossRefGoogle Scholar
  27. Dhillon, P., Yeole, B., Dikshit, R., Kurkure, A., & Bray, F. (2011). Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976–2005: An age–period–cohort analysis. British Journal of Cancer, 105(5), 723.CrossRefGoogle Scholar
  28. Dye, C., Maher, D., Weil, D., Espinal, M., & Raviglione, M. (2006). Targets for global tuberculosis control. International Journal of Tuberculosis and Lung Disease, 10(4), 460.Google Scholar
  29. Dye, C., Bassili, A., Bierrenbach, A., Broekmans, J., Chadha, V., Glaziou, P., et al. (2008). Measuring tuberculosis burden, trends, and the impact of control programmes. The Lancet Infectious Diseases, 8(4), 233–243.CrossRefGoogle Scholar
  30. Eradication ITF FD Control, CFD, & Prevention. (1993). Recommendations of the International task force for disease eradication. US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC).Google Scholar
  31. Forman, D., Bray, F., Brewster, D., Gombe Mbalawa, C., Kohler, B., & Piñeros, M. (2017) Cancer incidence in five continents (Vol. X, electronic version). Lyon: International Agency for Research on Cancer. 2013.Google Scholar
  32. Goodchild, M., Sahu, S., Wares, F., Dewan, P., Shukla, R. S., Chauhan, L. S., et al. (2011). A cost-benefit analysis of scaling up tuberculosis control in India. The International Journal of Tuberculosis and Lung Disease, 15(3), 358–362 http://www.ingentaconnect.com/content/iuatld/ijtld/2011/00000015/00000003/art00011.Google Scholar
  33. Gorman, S. (2013) ‘Is disease eradication always the best Path?’. March 20, 2013. Plos Medicine Pathogens Neglected Tropical Disease.Google Scholar
  34. Government of India. (2017). ‘‘Revised national TB control program annual status report.’’ New Delhi, Central TB Division, Directorate general of health services, ministry of health and family welfare.Google Scholar
  35. Haug, C. J. (2008a). Human papillomavirus vaccination – Reasons for caution. New England Journal of Medicine, 359(8), 861–862.  https://doi.org/10.1056/NEJMe0804638.CrossRefGoogle Scholar
  36. Haug, C. J. (2008b) Human papillomavirus vaccination – Reasons for caution. Mass Medical Soc.Google Scholar
  37. Hussain, R. S., McGarvey, S. T., Shahab, T., & Fruzzetti, L. M. (2012). Fatigue and fear with shifting polio eradication strategies in India: A study of social resistance to vaccination. PLoS One, 7(9), e46274.CrossRefGoogle Scholar
  38. John, T. J. (1976). Antibody response of infants in tropics to five doses of oral polio vaccine. British Medical Journal, 1(6013), 812.CrossRefGoogle Scholar
  39. John, T. J., & Vashishtha, V. M. (2012). Path to polio eradication in India: A major milestone. Indian Pediatrics, 49(2), 95–98.CrossRefGoogle Scholar
  40. Kaarthigeyan, K. (2012). Cervical cancer in India and HPV vaccination. Indian Journal of Medical and Paediatric Oncology, 33(1), 7–12.  https://doi.org/10.4103/0971-5851.96961.CrossRefGoogle Scholar
  41. Kass, N. E. (2001). An ethics framework for public health. American Journal of Public Health, 91(11), 1776–1782.CrossRefGoogle Scholar
  42. Kim, J. J., & Goldie, S. J. (2008). Health and economic implications of HPV vaccination in the United States. New England Journal of Medicine, 359(8), 821–832.  https://doi.org/10.1056/NEJMsa0707052.CrossRefGoogle Scholar
  43. LaMontagne, D. S., & Sherris, J. D. (2013). Addressing questions about the HPV vaccine project in India. The Lancet Oncology, 14(12), e492.CrossRefGoogle Scholar
  44. Lippman, A., Melnychuk, R., Carolyn Shimmin, B., Boscoe, M., & DU, R. (2007a). Human papillomavirus, vaccines and women’s health: Questions and cautions. Canadian Medical Association Journal, 177(5), 484–487.CrossRefGoogle Scholar
  45. Lippman, A., Melnychuk, R., Shimmin, C., & Boscoe, M. (2007b). Human papillomavirus, vaccines and women's health: Questions and cautions. Canadian Medical Association Journal, 177(5), 484–487.CrossRefGoogle Scholar
  46. Madhavi, Y., Puliyel, J. M., Mathew, J. L., Raghuram, N., Phadke, A., Shiva, M., et al. (2010). Evidence-based National Vaccine Policy.Google Scholar
  47. Mattheij, I., Pollock, A., & Brhlikova, P. (2012a). Do cervical cancer data justify HPV vaccination in India? Epidemiological data sources and comprehensiveness. Journal of the Royal Society of Medicine, 105(6), 250–262.CrossRefGoogle Scholar
  48. Mattheij, I., Pollock, A., & Brhlikova, P. (2012b). Do cervical cancer data justify HPV vaccination in India? Epidemiological data sources and comprehensiveness. Journal of the Royal Society of Medicine, 105(6), 250–262.CrossRefGoogle Scholar
  49. Minor, P. (2009). Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication. Vaccine, 27(20), 2649–2652.CrossRefGoogle Scholar
  50. Monie, A., Hung, C.-F., Roden, R., & Wu, T. C. (2008). Cervarix(™): A vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics: Targets & Therapy, 2(1), 107–113 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727782/.Google Scholar
  51. Nair, N., Wares, F., & Sahu, S. (2010). Tuberculosis in the WHO South-East Asia region. Bulletin of the World Health Organization, 88, 164–164 http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862010000300004&nrm=iso.CrossRefGoogle Scholar
  52. Nelson–Rees, W. A. (2001). Responsibility for truth in research. Philosophical Transactions of the Royal Society of London Series B: Biological Sciences, 356(1410), 849–851.CrossRefGoogle Scholar
  53. Paul, Y. (2004). Need for re-appraisal of acute flaccid paralysis (AFP) case classification. Vaccine, 22(29), 3829–3830.CrossRefGoogle Scholar
  54. Paul, Y. (2005a). Polio eradication programme: some ethical issues. Indian Journal of Medical Ethics, 2(4), 115–116.Google Scholar
  55. Paul, Y. (2005b). Polio eradication: Let us face the facts and accept the reality. Indian Pediatrics, 42(7), 728.Google Scholar
  56. Paul, Y., & Dawson, A. (2005). Some ethical issues arising from polio eradication programmes in India. Bioethics, 19(4), 393–406.CrossRefGoogle Scholar
  57. Porter, J., & Ogden, J. (1997). Ethics of directly observed therapy for the control of infectious diseases. Bulletin de l’Institut Pasteur, 95(3), 117–127.CrossRefGoogle Scholar
  58. Rajeswari, R., Balasubramanian, R., Muniyandi, M., Geetharamani, S., Thresa, X., & Venkatesan, P. (1999). Socio-economic impact of tuberculosis on patients and family in India. The International Journal of Tuberculosis and Lung Disease, 3(10), 869–877.Google Scholar
  59. Ramanathan, M., & Varghese, J. (2010). The HPV vaccine demonstration projects: We should wait, watch and learn. Google Scholar
  60. Rastogi, T., Devesa, S., Mangtani, P., Mathew, A., Cooper, N., Kao, R., et al. (2007). Cancer incidence rates among south Asians in four geographic regions: India, Singapore, UK and US. International Journal of Epidemiology, 37(1), 147–160.CrossRefGoogle Scholar
  61. Roberts, M. J., & Reich, M. R. (2002). Ethical analysis in public health. The Lancet, 359(9311), 1055–1059.CrossRefGoogle Scholar
  62. Rothman, K. J., Greenland, S., & Lash, T. L. (2008). Modern epidemiology. Philadelphia: Lippincott Williams & Wilkins.Google Scholar
  63. Sarojini, N., Srinivasan, S., Madhavi, Y., Srinivasan, S., & Shenoi, A. (2010). The HPV vaccine: Science, ethics and regulation. Economic and Political Weekly, 45(27), 27–34.Google Scholar
  64. Sciences CfIOoM. (2002). International ethical guidelines for biomedical research involving human subjects. Bulletin of Medical Ethics, 182.Google Scholar
  65. State, C. o., Epidemiologists, T., Gostin, L. O., & Hodge, J. G. (2004). Public health practice vs. Research: A report for public health practitioners including cases and guidance for making distinctions. Council of State and Territorial Epidemiologists.Google Scholar
  66. Sumner, A. (2012). Where do the poor live? World Development, 40(5), 865–877.  https://doi.org/10.1016/j.worlddev.2011.09.007.CrossRefGoogle Scholar
  67. Swaminathan, R., Shanta, V., Ferlay, J., Balasubramanian, S., Bray, F., & Sankaranarayanan, R. (2011). Trends in cancer incidence in Chennai city (1982–2006) and statewide predictions of future burden in Tamil Nadu (2007–16). Google Scholar
  68. Van Der Werf, M. J., & Borgdorff, M. W. (2007). How to measure the prevalence of tuberculosis in a population. Tropical Medicine & International Health, 12(4), 475–484.CrossRefGoogle Scholar
  69. WHO. (1991). Forty-fourth World Health Assembly, Resolutions and decisions. Resolution WHA 44.8. Geneva: World Health Organization. Report No. WHA44/1991/REC/1.Google Scholar
  70. WHO. (2005). Vaccine introduction guidelines: Adding a vaccine to a national immunization programme: Decision and implementation.Google Scholar
  71. Yang, D. Y., & Bracken, K. (2016). Update on the new 9-valent vaccine for human papillomavirus prevention. Canadian Family Physician, 62(5), 399–402 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865336/.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Giridhara R. Babu
    • 1
    • 2
  • A. Yamuna
    • 1
  1. 1.Public Health Foundation of India, Indian Institute of Public Health-HyderabadBengaluruIndia
  2. 2.Wellcome Trust-DBT India AllianceHyderabadIndia

Personalised recommendations